跳转至内容
Merck
CN

437644

Lipoproteins, Low Density, Human Plasma

别名:

LDL

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.25
UNSPSC Code:
12352202
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

≥95% (of total lipoprotein content, electrophoresis)

Quality Level

form

liquid

manufacturer/tradename

Calbiochem®

storage condition

do not freeze, protect from light

shipped in

wet ice

storage temp.

2-8°C

General description

A 10 mg vial contains ~2 mg of protein.
Native low density lipoproteins from human plasma. Cholesterol-carrier lipoprotein responsible for delivery of lipids (cholesterol) from liver to tissues. (Composition: 78-81% lipid; 19-22% protein. Note: 10 mg vial contains 2 mg of protein.)

Packaging

Please refer to vial label for lot-specific concentration.

Physical form

In 150 mM NaCl, 0.01% EDTA, pH 7.4.

Preparation Note

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
This product does not contain preservatives, so it is recommended that it be used under a laminar flow hood. Following initial use, this product is stable for 1 week at 2-8°C.

Other Notes

Foster, J.D., et al. 1993. Endocrinology132, 337.
Retsky, K.L., et al. 1993. J. Biol. Chem. 268, 1304.
Fielding, C.J. 1992. FASEB J. 6, 3162.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)


存储类别

12 - Non Combustible Liquids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Jean Baptiste Nyandwi et al.
International journal of molecular medicine, 49(5) (2022-03-23)
Endothelial dysfunction during diabetes has been previously reported to be at least in part attributed to increased oxidized low‑density lipoprotein (oxLDL) levels mediated by high glucose (HG) levels. Endothelial inflammation increases the adhesiveness of monocytes to the endothelium in addition
Lee D Chaves et al.
JCI insight, 6(11) (2021-04-30)
Patients with chronic kidney disease (CKD) and end-stage renal disease suffer from increased cardiovascular events and cardiac mortality. Prior studies have demonstrated that a portion of this enhanced risk can be attributed to the accumulation of microbiota-derived toxic metabolites, with



全球贸易项目编号

货号GTIN
437644-10MG04055977186819